Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared Benlazar S M’s post on X, adding:
“Talquetamab in RRMM (n=36; 33% RI)
- CRS 66.7% (grade ≥3: 8.3%), ICANS ~17–21%
- ORR day 30: 50% (RI) vs 45.8%
- ORR day 90: 66.7% (RI) vs 25%
- Dialysis ORR 80%
- PFS: 8.5 vs 2.6 mo (RI vs no-RI).”
Quoting Benlazar S M’s post:
“Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort .”
Title: Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort
Authors: Hossam M. Ali, Sandra Mazzoni, Utkarsh Goel, Jack Khouri, Faiz Anwer, Louis S. Williams, Diana Basali, Christy J. Samaras, Beth M. Faiman, Willem Van Heeckeren, Kimberly Hamilton, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Cynthia Scott, Saveta Mathur, Alexandra McDonald, Tara Roy, Julie Bevacqua, Marcelo C. Pasquini, Jason Valent, Shahzad Raza
Read the Full Article on Blood Cancer Journal
More posts featuring Mostafa Faisal.